Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

GRISACTIN

GRISEOFULVIN, MICROCRYSTALLINE

Standard Dose
250MG
Max Dose
Refer to approved labeling
Primary Use
Marketing status: Discontinued
Summary

Approval overview GRISACTIN is listed in Drugs@FDA under application 050051 (NDA).

Marketing status: Discontinued Active ingredient GRISEOFULVIN, MICROCRYSTALLINE Form and strength CAPSULE;ORAL - 250MG Sponsor WYETH AYERST Submission history Latest submission status date: 1996-05-09 00:00:00.

Structured Monograph

Clinical summary

Approval overview GRISACTIN is listed in Drugs@FDA under application 050051 (NDA). Marketing status: Discontinued Active ingredient GRISEOFULVIN, MICROCRYSTALLINE Form and strength CAPSULE;ORAL - 250MG Sponsor WYETH AYERST Submission history Latest submission status date: 1996-05-09 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued

Interaction Notes

  • No interaction notes stored yet.